Abstract
Scleromyxedema is an unusual skin disease that is characterized by a proliferation of fibroblasts and an accumulation of mucin. Despite experience with multiple forms of therapy, no single agent has proved uniformly beneficial in this condition. We describe a patient with scleromyxedema who was treated successfully with 2-chlorodeoxyadenosine (2-CdA), a purine analog used mainly in the treatment of lymphoproliferative disorders.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 288-290 |
| Number of pages | 3 |
| Journal | Journal of the American Academy of Dermatology |
| Volume | 35 |
| Issue number | 2 II |
| DOIs | |
| State | Published - Aug 1996 |
Fingerprint
ASJC Scopus subject areas
- Dermatology
Cite this
Treatment of scleromyxedema with 2-chlorodeoxyadenosine. / Davis, Loretta S.; Sanal, Salahattin; Sangueza, Omar P.
In: Journal of the American Academy of Dermatology, Vol. 35, No. 2 II, 08.1996, p. 288-290.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Treatment of scleromyxedema with 2-chlorodeoxyadenosine
AU - Davis, Loretta S.
AU - Sanal, Salahattin
AU - Sangueza, Omar P.
PY - 1996/8
Y1 - 1996/8
N2 - Scleromyxedema is an unusual skin disease that is characterized by a proliferation of fibroblasts and an accumulation of mucin. Despite experience with multiple forms of therapy, no single agent has proved uniformly beneficial in this condition. We describe a patient with scleromyxedema who was treated successfully with 2-chlorodeoxyadenosine (2-CdA), a purine analog used mainly in the treatment of lymphoproliferative disorders.
AB - Scleromyxedema is an unusual skin disease that is characterized by a proliferation of fibroblasts and an accumulation of mucin. Despite experience with multiple forms of therapy, no single agent has proved uniformly beneficial in this condition. We describe a patient with scleromyxedema who was treated successfully with 2-chlorodeoxyadenosine (2-CdA), a purine analog used mainly in the treatment of lymphoproliferative disorders.
UR - http://www.scopus.com/inward/record.url?scp=0030056419&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0030056419&partnerID=8YFLogxK
U2 - 10.1016/S0190-9622(96)90650-7
DO - 10.1016/S0190-9622(96)90650-7
M3 - Article
C2 - 8698907
AN - SCOPUS:0030056419
VL - 35
SP - 288
EP - 290
JO - Journal of the American Academy of Dermatology
JF - Journal of the American Academy of Dermatology
SN - 0190-9622
IS - 2 II
ER -